osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
 targeted therapy increases cure three key takeaways: 1 50% reduction in death for early stage nsclc w/ egfr mutation 2 improved cure rates w/ osimertinib
3 88% survival at 5 years #adaura #asco23 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | AD @PC31 | Incoming Chair @ASCO #CCC | Tweets my own | COI: https://t.co/ghKU8KhBvl